Background To evaluate the diagnostic performance of a combined serum biomarker panel for connective tissue disease-associated interstitial lung disease (CTD-ILD) and its correlation with disease severity. Methods This retrospective, cross-sectional study enrolled 200 CTD patients during October 2023 and October 2025, classifying them into CTD-ILD (n = 86) and CTD (n = 114) groups. General clinical characteristics, routine laboratory parameters, serum Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and surfactant protein D (SP-D) levels, serum ferritin (SF), pulmonary function, and the Composite Physiologic Index (CPI) were compared. The predictive power of the biomarker panel was evaluated via receiver operating characteristic (ROC) curves and DeLong’s test, while correlations with the CPI were assessed via Spearman’s correlation analysis. Results The groups were comparable in baseline characteristics and routine laboratory parameters. The CTD-ILD group exhibited significantly higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and all four serum biomarkers (KL-6, SP-A, SP-D, and SF) (all P 0.05), alongside impaired pulmonary function and a higher CPI ( P 0.05). The combined biomarker panel achieved an area under the curve of 0.980 (95% CI: 0.964–0.996), with 94.20% sensitivity and 95.60% specificity, significantly outperforming individual biomarkers (all P 0.05). All biomarkers demonstrated moderate to high positive correlations with the CPI ( r = 0.620, 0.520, 0.495, 0.402, respectively; P 0.001). Conclusion The combined serum biomarker panel demonstrated strong discrimination for CTD-ILD in this retrospective cohort and was significantly associated with disease severity.
Zhou et al. (Mon,) studied this question.